Processa Pharmaceuticals, Inc. Allowance for Loan and Lease Loss, Recovery of Bad Debts
Processa Pharmaceuticals, Inc. (PCSA) reported Allowance for Loan and Lease Loss, Recovery of Bad Debts of $5.15 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2017-09-25.
Discontinued › Notes
us-gaap:AllowanceForLoanAndLeaseLossRecoveryOfBadDebts · last filed 2017-09-25
- Processa Pharmaceuticals, Inc. allowance for loan and lease loss, recovery of bad debts for the quarter ending 2015-12-31 was $0.00.
- Processa Pharmaceuticals, Inc. allowance for loan and lease loss, recovery of bad debts for fiscal 2015 was $5.15K.
| Period end | Allowance for Loan and Lease Loss, Recovery of Bad Debts 3 month | Allowance for Loan and Lease Loss, Recovery of Bad Debts 9 month | Allowance for Loan and Lease Loss, Recovery of Bad Debts 12 month |
|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | $5.15K 10-K · filed 2017-09-25 | |
| 2015-09-30 | $5.15K 10-Q · filed 2017-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |